Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”

Benzer Materyaller

• Corrigendum to “Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany”
  Yazar:: Andreas Schneeweiss, ve diğerleri
  Baskı/Yayın Bilgisi: (2021-02-01)
• Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
  Yazar:: Hanna Huebner, ve diğerleri
  Baskı/Yayın Bilgisi: (2020-11-01)
• PARP inhibition with olaparib and talazoparib for HER2-negative advanced breast cancer—Results from the prospective PRAEGNANT registry
  Yazar:: Manuel Hörner, ve diğerleri
  Baskı/Yayın Bilgisi: (2026-04-01)
• The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
  Yazar:: Philipp Ziegler, ve diğerleri
  Baskı/Yayın Bilgisi: (2024-10-01)
• Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer
  Yazar:: Christina B. Walter, ve diğerleri
  Baskı/Yayın Bilgisi: (2025-04-01)